The purpose of this study is to assess the drug levels, immune response, safety and tolerability of BMS-986446 in healthy Chinese participants.
Participants must be of Chinese ethnicity (both biological parents are ethnically Chinese).
Participants must be Healthy adult male and female (as assigned at birth and non-pregnant and non-nursing).
Participants must have BMI of 18.0 to 28.0 kg/m2.
Participants must not have general history of any clinically significant gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrinological, immune-mediated, or hematological disorder; allergic disease; metabolic disorder; cancer; or cirrhosis.
Other protocol-defined Inclusion/Exclusion criteria apply.
Parallel
BMS-986446
DrugSpecified dose on specified days
Placebo
Other interventionSpecified dose on specified days
Maximum observed plasma concentration (Cmax)
Time of maximum observed plasma concentration (Tmax)
Area under concentration time curve from time 0 to time of last quantifiable concentration [AUC(0-T)]
Geometric mean ratios of area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]
Number of participants with anti-drug antibody (ADA) formation
Number of participants with adverse events (AEs)
Number of participants with vital sign abnormalities
Number of participants with 12-lead electrocardiogram (12-lead-ECG) abnormalities
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
